The upregulation of checkpoint inhibitors LAG-3, TIM-3, TIGIT, and VISTA on T cells post anti-PD-L1 ICB has been described in many tumors, including melanoma and non-small cell lung carcinoma (NSCLC), as a mechanism for acquired resistance [106]. This evidence concerns the gene TIGIT and non-small cell lung carcinoma.